Antibody Drug Conjugates Market
Business

Antibody Drug Conjugates Market Research Report 2020-2030

Stella Wilson Stella Wilson

The Antibody Drug Conjugates Market is projected to grow at an annualized rate of over 20%, till 2030

Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities.

Key Market Insights

  • Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
  • Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
  • The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
  • In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
  • A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
  • Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
  • Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
  • The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
  • In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
  • Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
  • Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
  • Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
  • With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
  • The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Table of Contents

  1. PREFACE
    1. Scope of the Report
    2. Research Methodology
    3. Chapter Outlines
  2. EXECUTIVE SUMMARY
  3. INTRODUCTION
    1. Chapter Overview
    2. Evolution of Anticancer Therapy
    3. Cancer Treatment Methods
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapies
    4. Monoclonal Antibody-Based Anticancer Therapies
    5. Components of Antibody Drug Conjugates (ADCs)
      1. Antibody
      2. Cytotoxin
      3. Linker
    6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
    7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
    8. Pharmacokinetic Properties of ADCs
      1. Absorption
      2. Distribution
      3. Metabolism and Excretion
  4. MARKET OVERVIEW
    1. Chapter Overview
    2. ADC Therapeutics: Clinical Pipeline
      1. Analysis by Phase of Development
      2. Analysis by Indication
      3. Analysis by Line of Treatment
      4. Analysis by Dosing Regimen
      5. Analysis by Type of Therapy
      6. Analysis by Target Antigen
      7. Analysis by Antibody Origin
      8. Analysis by Antibody Isotype
      9. Analysis by Type of Linker
      10. Analysis by Type of Payload / Warhead
      11. Key Technology Providers
      12. Discontinued Drugs
    3. ADC Therapeutics: Preclinical Pipeline
      1. Analysis by Phase of Development
      2. Analysis by Indication
      3. Analysis by Target Antigen
      4. Key Players: Analysis by Number of ADC Therapeutics
    4. ADC Therapeutics: Developer Landscape
      1. Analysis by Year of Establishment
      2. Analysis by Company Size
      3. Analysis by Geographical Location
      4. Logo Landscape: Analysis by Size and Target Indication
    5. Novel Drug Conjugates
  5. COMPANY AND DRUG PROFILES
    1. Chapter Overview
    2. AbbVie
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. Rovalpituzumab Tesirine / ROVA-T

5.2.3.1.1 Drug Overview

5.2.3.1.2. Mechanism of Action

5.2.3.1.3. Clinical Development Status

5.2.3.1.4. Key Clinical Trial Results

        1. Teliso-V / Telisotuzumab Vedotin / ABBV-399

5.2.3.2.1 Drug Overview

5.2.3.2.2. Mechanism of Action

5.2.3.2.3. Clinical Development Status

5.2.3.2.4. Key Clinical Trial Results

      1. Recent Developments and Future Outlook
    2. Astellas Pharma
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. Enfortumab Vedotin
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
        2. ASG16-M8F
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    3. AstraZeneca

54.1. Company Overview

5.4.2. Financial Information

5.4.3. Pipeline Overview

5.4.3.1. LUMOXITI™

5.4.3.1.1. Drug Overview

5.4.3.1.2. Mechanism of Action

5.4.3.1.3. Clinical Development Status

5.4.3.1.4. Key Clinical Trial Results

5.4.4. Recent Developments and Future Outlook

    1. Daiichi Sankyo
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. Trastuzumab deruxtecan / DS-8201a / DS 8201
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    2. ImmunoGen
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. IMGN853 / Mirvetuximab soravtansine
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    3. Immunomedics
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. IMMU-130
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    4. Pfizer
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
        2. MYLOTARG™ / Gemtuzumab Ozogamicin
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    5. Roche / Genentech
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. KADCYLA®
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
        2. RG-7596
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    6. Seattle Genetics
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. ADCETRIS®
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
        2. SGN- LIV1A
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    7. Synthon
      1. Company Overview
      2. Financial Information
      3. Pipeline Overview
        1. SYD985 / Trastuzumab Duocarmazine
          1. Drug Overview
          2. Mechanism of Action
          3. Clinical Development Status
          4. Key Clinical Trial Results
      4. Recent Developments and Future Outlook
    8. Other Companies
      1. Bayer HealthCare
        1. Company Overview
        2. Financial Information
        3. Pipeline Overview
        4. Recent Developments and Future Outlook
      2. Biotest Pharmaceuticals
        1. Company Overview
        2. Financial Information
        3. Pipeline Overview
        4. Recent Developments and Future Outlook
  2. KEY THERAPEUTIC AREAS
    1. Chapter Overview
    2. Hematological Malignancies
      1. Leukemias and Lymphomas
        1. Leukemia: Introduction and Epidemiology
          1. Acute Myeloid Leukemia
          2. Chronic Myeloid Leukemia
          3. Acute Lymphocytic Leukemia
          4. Chronic Lymphocytic Leukemia
        2. Lymphoma: Introduction and Epidemiology
        3. Current Treatment Landscape
        4. ADC Therapeutics for Leukemia / Lymphoma
      2. Multiple Myeloma
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Multiple Myeloma
    3. Solid Tumors
      1. Lung Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Lung Cancer
      2. Breast Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Breast Cancer
      3. Ovarian Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Ovarian Cancer
      4. Bladder Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Bladder Cancer
      5. Colorectal Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Colorectal Cancer
      6. Prostate Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Prostate Cancer
      7. Gastric Cancer
        1. Introduction and Epidemiology
        2. Current Treatment Landscape
        3. ADC Therapeutics for Prostate Cancer
  3. KEY OPINION LEADERS
    1. Chapter Overview
    2. Methodology
    3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
      1. Geographical Distribution of Key Opinion Leaders
        1. Experts on ADCETRIS®
        2. Experts on KADCYLA®
        3. Experts on MYLOTARG™
        4. Experts on Other ADCs
    4. Prominent Key Opinion Leaders (KOLs)
    5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
    6. Most Active Key Opinion Leaders
      1. Profile: KOL A (Celgene)
      2. Profile: KOL B (Western Regional Medical Center)
      3. Profile: KOL C (MedStar Washington Hospital Center)
      4. Profile: KOL D (Cancer Institute and Hospital)
      5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
      6. Profile: KOL F (Hopital Tenon)
      7. Profile: KOL G (Cleveland Clinic)
  4. TARGET COMPETITIVENESS ANALYSIS
    1. Chapter Overview
    2. Scope and Methodology
    3. Competitiveness Analysis: Key Clinical Targets for ADCs
      1. Four-Dimensional Bubble Analysis

8.3.2 Five-Dimensional Spider Web Analysis

    1. Competitiveness Analysis: Key Preclinical Targets for ADCs
      1. Two-Dimensional Scatter Plot Analysis

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Invite Friend to Read
Related Articles
Write a Comment

Home

Profile

Bloggers

Write

Blogs